Company news
Medrx Co., Ltd. (TSE:4586) news
Medrx Co., Ltd. news releases on 6ix. Latest, May 23, 2025: MedRx : Results of MRX-7MLL Phase I a Clinical Trial
Press releases & updates
MedRx : Results of MRX-7MLL Phase I a Clinical Trial
May 23, 2025
MedRx : Summary of Business Results for the First Quarter Ended March 31, 2025 (Consolidated)
May 20, 2025
MedRx : FDA Acceptance of New Drug Application for MRX-5LBT (“Lydolyte”)
April 2, 2025
MedRx : Summary of Business Results for the Third Quarter Ended September 30, 2024 (Consolidated)
November 8, 2024
MedRx : Start of MRX-7MLL Phase I a Clinical Trial
October 28, 2024
MedRx : H1 FY2024 Business Highlight & Financial Results
August 21, 2024
MedRx : Summary of Business Results for the Second Quarter Ended June 30, 2024 (Consolidated)
August 9, 2024
MedRx : Receipt of Complete Response Letter for MRX-5LBT
July 11, 2024
MedRx : Notice of revised forecasts of consolidated financial results
April 23, 2024
MedRx : Prospect of NDA Re-Submission for MRX-5LBT
October 10, 2023
MedRx : H1 FY2023 Business Highlight & Financial Results
August 28, 2023
MedRx : Summary of Business Results for the Second Quarter Ended June 30, 2023 (Consolidated)
August 18, 2023
MedRx : FY2022Business Highlight & Financial Results
March 2, 2023
MedRx : H1 FY2022 Business Highlight & Financial Results
August 29, 2022